AR045614A1 - Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos - Google Patents

Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos

Info

Publication number
AR045614A1
AR045614A1 ARP040103221A ARP040103221A AR045614A1 AR 045614 A1 AR045614 A1 AR 045614A1 AR P040103221 A ARP040103221 A AR P040103221A AR P040103221 A ARP040103221 A AR P040103221A AR 045614 A1 AR045614 A1 AR 045614A1
Authority
AR
Argentina
Prior art keywords
antibody
cdrs
human
cdr2
cdr3
Prior art date
Application number
ARP040103221A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42778436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR045614(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR045614A1 publication Critical patent/AR045614A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

Un anticuerpo unido a IL-1R humano y que inhibe la unión de IL-1 humano a IL-1R, caracterizado en que dicho anticuerpo es obtenible a partir de una línea celular de hibridoma MAK2D8 (DSM ACC2601) o es una variante de anticuerpo de epítopo reducido de linfocito T o humanizado, quimérico o un fragmento de dicho anticuerpo mostrando un valor de CI50 de 35 pM o inferior para la inhibición de la secreción mediada por IL-1 de I1-8 e IL-6 en células de fibroblasto humano del MRC5 (ATCC CCL 171) tiene propiedades beneficiosas para el tratamiento de enfermedades inflamatorias. Reivindicación 9: El uso de un anticuerpo de acuerdo con las reivindicaciones 1 a 8 para la elaboración de una composición farmacéutica. Reivindicación 13: Un ácido nucleico codificando un polipéptido capaz de ensamblarse respectivamente junto con la otra cadena de anticuerpo definida posteriormente, mientras que dicho polipéptido es también a) una cadena pesada de anticuerpo comprendiendo como CDRs CDR1 (aa 45- 54), CDR2 (aa 69-84) y CDR3 (aa 117-123) de ID de SEC Nº: 1, o b) una cadena ligera de anticuerpo comprendiendo como CDRs CDR1 (aa 43-57), CDR2 (aa 73-79) y CDR3 (aa 112-120) de ID de SEC Nº:2.
ARP040103221A 2003-09-10 2004-09-08 Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos AR045614A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50168103P 2003-09-10 2003-09-10
EP03029659 2003-12-23

Publications (1)

Publication Number Publication Date
AR045614A1 true AR045614A1 (es) 2005-11-02

Family

ID=42778436

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103221A AR045614A1 (es) 2003-09-10 2004-09-08 Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos

Country Status (13)

Country Link
US (2) US20050118169A1 (es)
EP (1) EP1664121B1 (es)
JP (1) JP2007527230A (es)
AR (1) AR045614A1 (es)
AT (1) ATE435872T1 (es)
AU (1) AU2004270390A1 (es)
BR (1) BRPI0414259A (es)
CA (1) CA2538319A1 (es)
MX (1) MXPA06002728A (es)
NZ (1) NZ545761A (es)
RU (1) RU2369617C2 (es)
TW (1) TWI295672B (es)
WO (1) WO2005023872A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2322622A3 (en) 2005-03-25 2012-03-07 National Research Council of Canada Method for isolation of soluble polypeptides
TWI391399B (zh) 2005-05-25 2013-04-01 Hoffmann La Roche 測定溶離多肽之鹽濃度之方法
US10155816B2 (en) 2005-11-28 2018-12-18 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
JP2009517069A (ja) 2005-12-01 2009-04-30 ドマンティス リミテッド インターロイキン１受容体１型に結合する競合ドメイン抗体フォーマット
CN101460522B (zh) * 2006-04-11 2014-07-23 弗·哈夫曼-拉罗切有限公司 糖基化抗体
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
WO2009014835A2 (en) * 2007-06-21 2009-01-29 Angelica Therapeutics, Inc. Modified toxins
EP2170949B1 (en) 2007-07-17 2012-12-26 F. Hoffmann - La Roche AG Variable tangential flow filtration
WO2009110944A1 (en) * 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
US8298533B2 (en) 2008-11-07 2012-10-30 Medimmune Limited Antibodies to IL-1R1
WO2010080463A1 (en) * 2008-12-18 2010-07-15 Imclone Llc Antibody humanization
ES2628839T3 (es) 2009-10-19 2017-08-04 F. Hoffmann-La Roche Ag Anticuerpos anti-IgG sin reactividad cruzada
KR101436219B1 (ko) 2009-10-26 2014-09-01 에프. 호프만-라 로슈 아게 글리코실화된 면역글로불린의 제조 방법
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
BR112013007293A2 (pt) 2010-10-05 2016-06-14 Hoffmann La Roche anticorpos contra a tweak de seres humanos e suas utilizações
US20140308294A1 (en) 2011-04-15 2014-10-16 Merck Patent Gmbh Anti-IL-1R1 Inhibitors For Use in Cancer
US9365881B2 (en) 2011-10-05 2016-06-14 Hoffmann-La Roche Inc. Process for antibody G1 glycoform production
EP3091029B1 (en) * 2011-10-31 2022-12-28 F. Hoffmann-La Roche AG Anti-il13 antibody formulations
WO2013148232A1 (en) * 2012-03-27 2013-10-03 Genentech, Inc. Methods of prognosing, diagnosing and treating idiopathic pulmonary fibrosis
WO2014150600A2 (en) 2013-03-15 2014-09-25 Angelica Therapeutics, Inc. Modified toxins
CN105324487B (zh) 2013-05-29 2020-01-17 豪夫迈·罗氏有限公司 唾液酸化的定量控制
WO2015001033A1 (en) 2013-07-05 2015-01-08 F. Hoffmann-La Roche Ag Process for the mono- and bi-sialylation of glycoproteins employing n-terminally truncated beta-galactoside alpha-2,6-sialyltransferase mutants
US10610104B2 (en) 2016-12-07 2020-04-07 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20200315540A1 (en) 2016-12-14 2020-10-08 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
UY37651A (es) 2017-03-31 2018-10-31 Swedish Orphan Biovitrum Ab Publ Polipéptido de unión al il-1r-i
EP3638697A4 (en) 2017-06-12 2021-07-07 Bluefin Biomedicine, Inc. ANTI-IL1RAP ANTIBODIES AND ANTIBODY INGREDIENT CONJUGATES
WO2020106750A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) * 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) * 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4496689A (en) * 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
DE3675588D1 (de) * 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5204244A (en) * 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) * 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US6511665B1 (en) * 1987-11-25 2003-01-28 Immunex Corporation Antibodies to interleukin-1 receptors
US6652854B2 (en) * 2000-08-08 2003-11-25 Immunex Corporation Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30L

Also Published As

Publication number Publication date
TW200513261A (en) 2005-04-16
AU2004270390A1 (en) 2005-03-17
US20090191187A1 (en) 2009-07-30
TWI295672B (en) 2008-04-11
NZ545761A (en) 2008-10-31
BRPI0414259A (pt) 2006-11-07
JP2007527230A (ja) 2007-09-27
EP1664121A1 (en) 2006-06-07
ATE435872T1 (de) 2009-07-15
US20050118169A1 (en) 2005-06-02
RU2369617C2 (ru) 2009-10-10
CA2538319A1 (en) 2005-03-17
EP1664121B1 (en) 2009-07-08
RU2006111579A (ru) 2007-10-27
MXPA06002728A (es) 2006-06-06
WO2005023872A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
AR045614A1 (es) Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US20220340676A1 (en) Modified human igm constant regions for modulation of complement-dependent cytolysis effector function
AU2011329647B2 (en) Neutralizing anti-CCL20 antibodies
RU2020111211A (ru) Способы лечения состояний, ассоциированных с masp-2-зависимой активацией комплемента
PE20120815A1 (es) Anticuerpos anti il-17f y metodos de uso de los mismos
AR068508A1 (es) Anticuerpo capaz de enlazar linfopoyetina estromal timica
EP2970481A2 (en) Human antibodies to nav1.7
JP2016512551A5 (es)
NZ732922A (en) Tumor necrosis factor (tnf) superfamily receptor binding molecules and uses thereof
PE20110225A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
PE20121579A1 (es) Proteinas de enlace al antigeno il-23 humanas
CO6231009A2 (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
NO20074867L (no) Antistoffer mot CCR5 og anvendelser derav
EP3145539A1 (en) Human antibodies to middle east respiratory syndrome -coronavirus spike protein
RU2011137369A (ru) Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента
NZ717847A (en) Human antigen binding proteins that bind beta-klotho, fgf receptors and complexes thereof
RU2013125457A (ru) Комбинация антител против с-мет
AR014459A1 (es) Un anticuerpo monoclonal para la il-12 humana, hibridoma que produce a dicho anticuerpo, composicion farmaceutica que comprende al citado anticuerpo, y uso de dicho anticuerpo para la preparacion de medicamentos
RU2011140509A (ru) Гетеродимерные полипептиды il-17a/f и возможности их лечебного применения
EA200901154A1 (ru) Растворимые слитые белки il17ra/rc и родственные способы
AR111830A1 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
RU2013145623A (ru) Fc ВАРИАНТЫ АНТИТЕЛА
RU2010120879A (ru) Антитела против g-белка распираторно-синцитиального вируса (rsv)
PE20240142A1 (es) Anticuerpos inhibidores via del factor tisular y usos de los mismos
WO2009054873A4 (en) Anti-rantes antibodies and methods of use thereof

Legal Events

Date Code Title Description
FB Suspension of granting procedure